MediWound Announces Exercise of Over-Allotment Option
March 22, 2022 16:05 ET
|
MediWound Ltd.
YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective,...
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
March 21, 2022 07:30 ET
|
MediWound Ltd.
Primary Endpoint Met with Highly Statistically Significant ResultsFinal Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:...
MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022 07:00 ET
|
MediWound Ltd.
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022...
MediWound Announces Closing of Public Offering of Ordinary Shares
March 10, 2022 17:05 ET
|
MediWound Ltd.
YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective,...
MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
March 10, 2022 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
MediWound Announces Pricing of Public Offering of Ordinary Shares
March 03, 2022 08:30 ET
|
MediWound Ltd.
YAVNE, Israel, March 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective,...
MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
March 02, 2022 16:24 ET
|
MediWound Ltd.
YAVNE, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“Mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective,...
MediWound to Present at Upcoming Investor Conferences in March
March 01, 2022 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair...
MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army
February 17, 2022 06:00 ET
|
MediWound Ltd.
YAVNE, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair...
MediWound to Present at Upcoming Investor Conferences in February
February 14, 2022 09:03 ET
|
MediWound Ltd.
YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...